BEARDSWORTH LAUNCHES ADVANCED CLINICAL TRIAL MANAGEMENT SYSTEM TO HELP DRUG RESEARCHERS EXPEDITE GLOBAL TRIALS

FLEMINGTON, NEW JERSEY (January 2, 2008)

A new Clinical Trial Management System (CTMS) is changing how clinical trial data is reported to the pharmaceutical industry. This new system is offered to drug companies conducting Phase I through IV trials with Beardsworth, a full service contract research organization (CRO). The advanced system integrates real-time data into the actual clinical trial process.

Beardsworth's new CTMS, called BNet3, improves the company's previous system because it accommodates both the value of standardization and the flexibility of customization. Its modular approach provides data to users quickly and accurately, in the format they require.

"It's a unique system because our process allows real-time tracking and updating of metrics from the field," said Michael O'Brien, president and chief executive officer.

With that ease comes a great global opportunity. Global trials let drug developers put their footprints right where the potential patients are, making the research more accurate and effective.

"This lets us run and manage global clinical trials using a Web-based tool users can access anywhere," said O'Brien. "To our clients, this offers a new level of transparency to view critical project data and the related metrics of their studies," said O'Brien.

Making this data more transparent makes CROs much more accountable. At any moment, clients can log in securely and review a research project's status. They'll know what's been done, what is scheduled and what data is available for review. Because the client and CRO team use the same CTMS, there are no delays in data access.

"Few CROs offer this accountability. Few offer clients more than a look at their data repository. Access to live data in our trial processes is a significant improvement in how global clinical trials are handled," said Steven Trigilio, chief technology officer.

BNet3 was tested this winter and went live January 2, 2008. Like Beardsworth's earlier versions, the system integrates operations, data management and clinical trial management. It is 21 CFR Part 11 compliant and monitors all aspects of a clinical trial's life cycle. Trigilio said an upgrade in 2008 will support secure electronic signatures.

To review BNet3 or experience how it can support global clinical trials in the pharmaceutical, biotechnology or medical device industries, visit www.beardsworth.com or call 800-788-6046.

About Beardsworth

BEARDSWORTH is a privately held full-service contract research organization (CRO), providing a complete range of clinical, data management, regulatory, and medical writing services in Phase I through IV to the pharmaceutical, biotechnology, and medical device industries. The company specializes in complex clinical trials, with a primary focus in oncology, and other difficult therapeutic areas. BEARDSWORTH is celebrating its 21st year in business, and is a WBENC-certified woman-owned business. For more information about BEARDSWORTH, visit the website at www.beardsworth.com.

###